Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3

International Journal of Cancer

Volumn 108, Issue 5, 2004, Pages 733-740

  Singh, Rana P ^a   Tyagi, Anil K ^a   Dhanalakshmi, Sivanandhan ^a   Agarwal, Rajesh ^a,b   Agarwal, Chapla ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Angiogenesis; Apoptosis; Cell proliferation; Grape seed extract; Prostate cancer

Indexed keywords

GRAPE SEED EXTRACT; PLANT EXTRACT; SOMATOMEDIN BINDING PROTEIN 3; TRACONOL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONTENT; PROTEIN SECRETION; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL DIVISION; DIET; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITIS;

EID: 0346024122     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11620     Document Type: Article

References (50)

1. Baldini N. Multidrug resistance-a multiplex phenomenon. Nat Med 1997;3:378-80.
2. Pilat MJ, Kamradt JM, Pienta KJ. Hormone resistance in prostate cancer. Cancer Metastasis Rev 1998-99;17:373-81.
3. Aquilina JW, Lipsky JJ, Bostwick DG. Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst 1997;89:689-96.
4. Yu R, Mandlekar S, Ruben S, Ni J, Kong AT. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 2000;60:2384-9.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nat Med 2000;407:249-57.
6. Singh DK, Lippman SM. Cancer chemoprevention Part 2: hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. Oncology 1998;12:1787-800.
7. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-7.
8. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-9.
9. Bartolome B, Hernandez T, Bengoechea ML, Quesada C, Gomez-Cordoves C, Estrella I. Determination of some scructural features of procyanidins and related compounds by photodiode-array detection. J Chromatogr A 1996;723:19-26.
10. Escribano-Bailon MT, Gutierrez-Fernandez Y, Rivas-Gonzalo JC, Santos-Buelga C. Characterization of procyanidins of Vitis vinifera variety Tinta del París Paris grape seeds. J Agric Food Chem 1992;40:1794-9.
11. Bagchi D, Garg A, Krohn RL, Bagchi M, Tran MX, Stohs SJ. Oxygen free radical scavenging abilities of vitamin C and E, and a grape seed proanthocyanidin extract in vitro. Res Commun Mol Pathol Pharmacol 1997;95:179-89.
12. Bagchi D, Garg A, Krohn RL, Bagchi M, Bagchi DJ, Balmoori J, Stohs SJ. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen Pharmacol 1998;30:771-6.
13. Maffei-Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 1996;62:495-502.
14. Halpern MJ, Dahlgren AL, Laakso I, Seppanen-Laakso T, Dahlgren J, McAnulty PA. Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. J Int Med Res 1998;26:171-80.
15. Agarwal C, Sharma Y, Zhao J, Agarwal R. A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing G1 arrest and differentiation. Clin Cancer Res 2000;6:2921-30.
16. Ye X, Krohn RL, Liu W, Joshi SS, Kuszynski CA, McGinn TR, Bagchi M, Preuss HG, Stohs SJ, Bagchi D. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol Cell Biochem 1999;196:99-108.
17. Arii M, Miki M, Hosoyama R, Ariga H, Yamaji N, Kataoka S. Chemopreventive effect of grape seed extract on intestinal carcinogenesis in the APCMin mouse. Proc Am Assoc Cancer Res 1998;39:20.
18. Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumor promoting activity of a polyphenolic fraction isolated from grape seeds in mouse skin two-stage initiation-promotion protocol, and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis 1999;20:1737-45.
19. Agarwal C, Sharma Y, Agarwal R. Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell cycle regulators, and induction of G1 arrest and apoptosis. Mol Carcinog 2000;28:1-10.
20. Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000;92:94-5.
21. Bostwick DG, Iczkowski KA. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998:16:118-23.
22. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
23. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Henneken CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
24. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomark Prev 2001;10:421-7.
25. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor 1 (IGF-1), IGF-2, IGF-binding protein-3 and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
26. Singh RP, Tyagi AK, Zhao J, Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen activated protein kinases and induction of apoptosis. Carcinogenesis 2002;23:499-510.
27. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DCF, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice, and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002;62:3063-9.
28. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505-15.
29. Brawer MK. Quantitative microvessel density: a staging and prognostic marker for human prostatic carcinoma. Cancer 1996;78:345-9.
30. Ali IU, Senger DR, Smith LEH. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology 2001;57:143-7.
31. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 1991;51:2780-5.
32. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 1992;52:5887-92.
33. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
34. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-7.
35. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
36. Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in anti-proliferation and apoptosis. Oncogene 2003;22:1302-16.
37. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 2002;23:1869-76.
38. Gimbrone MA Jr, Leapman S, Cotran R, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-76.
39. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
40. Boehm T, Folkman J, Browder T, O'Really MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
41. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-4.
42. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL, Bicknell R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87:435-9.
43. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25.
44. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
45. McLesky SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessel independent of the transfected angiogenic factor. Am J Pathol 1998;153:1993-2006.
46. Borgstrom P, Hillan KJ, Sriramarao P, Ferrera N. Complete inhibition of angiogenesis and growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-9.
47. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrera N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10.
48. Singh RP, Agarwal R. Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 2003;3:205-17.
49. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000;97:3455-60.
50. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001;98:10350-5.